by Hepatology Knowledge Into Practice
A summary of new trial data, guideline recommendations and expert opinion across hepatology care, run by Hepatology Knowledge into Practice (https://hepatology.knowledgeintopractice.com), featuring interviews with leading experts from across the globe. This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes.
Language
🇺🇲
Publishing Since
4/19/2022
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
June 7, 2022
<p>NASH has historically had very few treatment options, with none currently indicated specifically for NASH. But a large number of ongoing clinical trials means that treatment may look different in the future.</p> <p>Join Professor Philip Newsome for an overview of current treatments in NASH, as well as how treatment may change in the future.</p> <p>By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at hepatology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.</p> <p><strong>References:</strong></p> <p>References are available <a href="https://hepatology.knowledgeintopractice.com/learning/podcast/nash-current-and-future-therapies/pre-assessment">here</a></p> <p><strong>Disclosures:</strong></p> <p>Prof. Philip Newsome declares the following:</p> <p>Consultant on behalf of the University of Birmingham: Boehringer Ingelheim, Novo Nordisk, Intercept, BMS, Gilead, Poxel Pharmaceuticals</p> <p>Grants/Research Support recipient: Novo Nordisk, Boehringer Ingelheim</p> <p>Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.</p> <p>The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.</p> <p>Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.</p>
May 25, 2022
<p>NASH occurs in around 20% of individuals with NAFLD, and puts patients at high risk of poor outcomes including cardiovascular events and hepatocellular carcinoma. With people with type 2 diabetes and obesity at significantly increased risk for developing NAFLD, how can we identify those with NASH?</p> <p>In this podcast episode, we are joined by Dr Kenneth Cusi to discuss how patients can be risk stratified using non-invasive biomarkers and imaging techniques.</p> <p>By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at <a href="https://hepatology.knowledgeintopractice.com/" target="_blank">hepatology.knowledgeintopractice.com</a>, where you can find all past episodes of the podcast as well as other free CME resources.</p> <p><strong>References:</strong></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/28225987/" rel="noreferrer noopener" target="_blank"><u>Nones RB et al. Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist? Arch Endocrinol Metab. 2017 May-Jun;61(3):276-281.</u></a></p> <p><a href="https://linkinghub.elsevier.com/retrieve/pii/S1542-3565(09)00533-3" rel="noreferrer noopener" target="_blank"><u>Shah AG et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12.</u></a></p> <p><a href="https://linkinghub.elsevier.com/retrieve/pii/S2468-1253(19)30383-8" rel="noreferrer noopener" target="_blank"><u>Newsome PN et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373.</u></a></p> <p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644799/" rel="noreferrer noopener" target="_blank"><u>European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. </u><u>Obes Fact</u><u>s 2016;9(2):65-90.</u></a></p> <p><strong>Disclosures:</strong></p> <p>Dr Kenneth Cusi disclosures are as follows:</p> <p>Research Support - Poxel, Zydus, Echosens, Inventiva, Novo Nordisk</p> <p>Consultant - Allergan, Altimmune, Arrowhead, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Genentech, Gilead, Intercept, Janssen, Pfizer, Prosciento, Madrigal, and Novo Nordisk.</p> <p>Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.</p> <p>The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.</p> <p>Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.</p>
April 19, 2022
<p>People with type 2 diabetes or obesity are at higher risk of developing non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH). Some estimates report a prevalence of NAFLD of 60% in people with type 2 diabetes, rising to 78% in those who also have obesity. So what’s behind this link?</p> <p>In this podcast episode, Professor Giulio Marchesini explores the relationships between NAFLD, type 2 diabetes and obesity and offers advice for healthcare professionals caring for people with one or more of these conditions.</p> <p>By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at <a href="//hepatology.knowledgeintopractice.com">hepatology.knowledgeintopractice.com</a>, where you can find all past episodes of the podcast as well as other free CME resources.</p> <p><strong>References:</strong></p> <ul> <li><a href="https://pubmed.ncbi.nlm.nih.gov/28953675/" rel="noreferrer noopener" target="_blank"><u>Dai W, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore). 2017 Sep;96(39):e8179.</u></a></li> <li><a href="https://pubmed.ncbi.nlm.nih.gov/34557367/" rel="noreferrer noopener" target="_blank"><u>Padda J, et al. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus. 2021 Aug 20;13(8):e17321.</u></a></li> <li><a href="https://diabetesjournals.org/care/article/41/2/372/30381/Nonalcoholic-Fatty-Liver-Disease-and-Risk-of" rel="noreferrer noopener" target="_blank"><u>Mantovani A, et al. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2018 Feb; 41(2):372-382.</u></a></li> <li><a href="https://pubmed.ncbi.nlm.nih.gov/18058083/" rel="noreferrer noopener" target="_blank"><u>Targher G, et al. Diabetologia. 2008 Mar; 51(3):444-50.</u></a></li> <li><a href="https://pubmed.ncbi.nlm.nih.gov/32684985/" rel="noreferrer noopener" target="_blank"><u>Godoy-Matos AF, et al. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020 Jul 14;12:60.</u></a></li> <li><a href="https://pubmed.ncbi.nlm.nih.gov/32044314/" rel="noreferrer noopener" target="_blank"><u>Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1999-2014.e1.</u></a></li> <li><a href="https://pubmed.ncbi.nlm.nih.gov/26226099/" rel="noreferrer noopener" target="_blank"><u>Kim D, et al. Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016 Jan;14(1):132-8.e4.</u></a></li> </ul> <p><strong>Disclosures:</strong> Prof. Giulio Marchesini declares the following:</p> <p>Advisory Board: Novartis, Eli Lilly, Gilead, MSD, Pfzier, Astra-Zeneca</p> <p>Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.</p> <p>The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.</p> <p><strong>Funding:</strong> This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.</p>
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
A summary of new trial data, guideline recommendations and expert opinion across hepatology care, run by Hepatology Knowledge into Practice (https://hepatology.knowledgeintopractice.com), featuring interviews with leading experts from across the globe.
This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes.
This podcast updates daily.
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Yes, this podcast regularly features guests.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.